Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by
ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by …

Most patients with myelodysplastic syndromes (MDS) require therapeutic intervention.
However, there are few approved treatments for MDS. To explore reasons, we searched …

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic
investigation and evaluation of cytopenias of uncertain origin and suspected …

A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy
and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients …

During the process of hematopoiesis, hematopoietic stem cells (HSCs) undergo hierarchical
differentiation and maturation to develop into mature effector cells through a tightly regulated …

Somatic mutations in the splicing factor SF3B1 occur in about onethird of all myelodysplastic
neoplasms (MDS) and define a subgroup of patients characterized by ring sideroblasts (RS) …

The unique heterogenous landscape of myelodysplastic syndromes/neoplasms (MDS) has
resulted in continuous redefinition of disease sub-entities, in view of the novel translational …

Background Myelodysplastic syndromes (MDS) comprise a heterogeneous group of
diseases classified by comprehensive diagnostics. Identification of homogeneous …

Analysis of erythroid lineage features in myelodysplastic syndromes patients with SF3B1
gene mutation Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …

Las neoplasias mielodisplásicas representan uno de los retos diagnósticos más complejos
entre las neoplasias hematológicas. Debido a su alta variabilidad tanto en manifestaciones …